Rhythm Pharmaceuticals Inc (RYTM) reported disappointing financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) came in at $-0.82, missing Wall Street's consensus estimate of $-0.74 by $0.08. Revenue matched expectations at $0.1 billion, but this figure still reflects a shortfall in overall performance.
The company, a commercial-stage biopharmaceutical firm based in Boston, focuses on developing therapeutics for rare diseases, particularly its melanocortin-4 receptor (MC4R) agonists. Its lead asset, IMCIVREE, is approved by the Food and Drug Administration (FDA) for chronic weight management in patients with specific genetic conditions related to obesity.
Rhythm Pharmaceuticals will host an earnings conference call at 8:00 AM ET to discuss these results and provide additional insights into its business performance. Investors are encouraged to review the full earnings release and management's commentary for a comprehensive understanding of the quarter's results and future prospects.
Upcoming earnings estimates suggest an EPS of $-0.7613 and revenue of $0.1 billion for the next reporting period on August 2, 2026. The company's current market capitalization stands at $6.62 billion, with a trailing twelve-month EPS of $-2.93.